TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04328441
Drug: BCG Vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
Study: NCT01520688
Drug: Fluticasone, Budesonide, Beclomethasone
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
Study: NCT01520688
Drug: Fluticasone, Beclomethasone, Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
Study: NCT01520688
Drug: Budesonide, Fluticasone, Beclomethasone
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
Study: NCT01520688
Drug: Budesonide, Beclomethasone, Fluticasone
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
Study: NCT01520688
Drug: Beclomethasone, Fluticasone, Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
Study: NCT01520688
Drug: Beclomethasone, Budesonide, Fluticasone
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
Study: NCT03733132
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin treatment of 2500mg for 10 months in the Metformin group
Study: NCT02506634
Drug: Esomeprazole MUPS, 20 mg
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
Study: NCT04385186
Drug: Inactivated convalescent plasma
Normalized name: Heat inactivated convalescent plasma
DrugBank: V-SARS (DB15812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma
Study: NCT00135889
Drug: Femoral perineural infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00234923
Drug: lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg lopinavir/ 100 mg ritonavir, BID
Study: NCT00234923
Drug: lamivudine/zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg lamivudine/150mg zidovudine, BID
Study: NCT00149630
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
Study: NCT00427557
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
Study: NCT00427557
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m\^2 by vein for 1 Day (Day -7).
Study: NCT00427557
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
Study: NCT04681768
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
Study: NCT03357640
Drug: combined oral contraceptive pills
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
Study: NCT02968004
Drug: MOD-4023
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Once weekly subcutaneous injection using pre-filled pen device.
Study: NCT02968004
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily subcutaneous injection of Genotropin using pre-filled pen device.
Study: NCT02104609
Drug: Levonorgestrel 1.5mg by mouth once
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
Study: NCT00207844
Drug: Selenium as sodium selenite
Normalized name: SELENIUM (AS SODIUM SELENATE)
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02378545
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
Study: NCT02857491
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.5 mg ranibizumab before vitrectomy
Study: NCT01365403
Drug: carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multiple oral doses, Days 1-24 of study period 2
Study: NCT02306564
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given to patients at high risk for OHSS
Study: NCT04594330
Drug: virgin coconut oil (VCO)
Normalized name: Coconut Oil
DrugBank: Coconut (DB10523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of VCO twice a day for 14 days
Study: NCT02599844
Drug: Iodohippurate
Normalized name: IODOHIPPURATE
DrugBank: Iodohippuric acid (DB15445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
Study: NCT02599844
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
Study: NCT00697814
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene 50 mg/day for 12 weeks
Study: NCT05386446
Drug: Interferon gamma human recombinant (IFN-G)
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal form
Study: NCT01564563
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Study: NCT01564563
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Study: NCT02931123
Drug: lattulose and rifaximine
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02951117
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT02951117
Drug: ABBV-838
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02951117
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet or intravenous infusion
Study: NCT02052323
Drug: Artesunate/mefloquine (AS/MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
Study: NCT00611767
Drug: Thiopental
Normalized name: Thiopental
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Study: NCT01791465
Drug: extended-release exenatide
Normalized name: Exenatide for Extended-Release Injectable Suspension
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single arm study - 2mg Bydureon every 7 days x 16 weeks
Study: NCT00913913
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10mg/kg iv every 2 weeks
Study: NCT00686517
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Study: NCT03862833
Drug: IL2
Normalized name: Ad-IL2
DrugBank: TG1024 (DB06180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40
Study: NCT04071769
Drug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
Study: NCT02784847
Drug: Triheptanoin
Normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
Study: NCT05679830
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
Study: NCT00722215
Drug: BQ-123 (selective endothelin A receptor antagonist)
Normalized name: ethanol
DrugBank: BQ-123 (DB12054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
Study: NCT00722215
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of nifedipine 10 mg given orally as active control
Study: NCT02638415
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
Study: NCT01188252
Drug: Roniciclib (BAY1000394)
Normalized name: Roniciclib
DrugBank: Roniciclib (DB12974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT02390258
Drug: 10mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390258
Drug: 30mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390258
Drug: 60mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390258
Drug: 120mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390258
Drug: 200mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390258
Drug: 150mg XEN-D0103
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00882635
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency
Study: NCT00776490
Drug: Glimepiride 1mg Tablets
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01998113
Drug: Glyburide vs Insulin trials
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affecting groups 1 and 2
Study: NCT01998113
Drug: Metformin vs Insulin trials
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Affecting groups 3 and 4
Study: NCT00882635
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
Study: NCT01998113
Drug: Metformin vs Glyburide trials
Normalized name: glyburide / metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Affecting groups 5 and 6
Study: NCT00537771
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg once daily oral dose
Study: NCT00537771
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg once daily oral dose
Study: NCT01693614
Drug: Buparlisib
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
Study: NCT02575300
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT02078089
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine will be given to patients as part of their standard care
Study: NCT02400151
Drug: Vitamin D supplementation
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
Study: NCT02161653
Drug: Prednisone plus Metadoxine
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02161653
Drug: Pentoxifylline plus Metadoxine
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00562913
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
Study: NCT02375581
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg, Po, TID during RT
Study: NCT00334698
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00334698
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00334698
Drug: Cetirizine with Pseudoephedrine
Normalized name: cetirizine / pseudoephedrine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03781388
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
Study: NCT01438775
Drug: NX-1207
Normalized name: NX-1207
DrugBank: NX-1207 (DB05493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg NX-1207 in 10 mL saline vehicle
Study: NCT04585841
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive cannabidiol in the period of time they receive chemotherapy.
Study: NCT00390650
Drug: Saredutant
Normalized name: Saredutant
DrugBank: Saredutant (DB06660)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01663012
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02926638
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02162420
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
Study: NCT02162420
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
Study: NCT02162420
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
Study: NCT00307450
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: up to 200 mg per day in two dosages per day.
Study: NCT04846491
Drug: Peginterferon alfa-2b injection
Normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study: NCT04846491
Drug: Peginterferon alfa-2b injection
Normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study: NCT04846491
Drug: TDF
Normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
Study: NCT04846491
Drug: Peginterferon alfa-2b injection
Normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study: NCT02854761
Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Normalized name: Klor-Con/EF
DrugBank: EF-022 (DB17768)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02465489
Drug: Deferiprone extended release
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 1000 mg extended release tablet formulation
Study: NCT02465489
Drug: Deferiprone immediate release
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferriprox (deferiprone) 500 mg immediate release tablet formulation
Study: NCT03160898
Drug: Reldesemtiv
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02231684
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).